Itrasel 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent effective against a variety of fungal infections. Itraconazole acts by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to fungal cell death. It is indicated for the treatment of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itrasel 100 Capsule is administered orally and exhibits good bioavailability, with absorption enhanced when taken with food. The drug undergoes hepatic metabolism primarily via the cytochrome P450 3A4 enzyme system, necessitating caution when co-administered with other medications metabolized by this pathway due to potential drug interactions. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Liver function monitoring is recommended during prolonged therapy due to the risk of hepatotoxicity. Itrasel 100 Capsule should be used under medical supervision, with dosage adjustments based on the severity of infection and patient response. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals and in those with severe hepatic impairment.